Strano tijelo u mokraćnom mjehuru kao ishod samokateterizacije: prikaz slučaja

Foreign bodies inside urinary tract are a relatively rare condition in our practice. There are several reports published and in most cases the reason for self insertion of an object was autoerotic stimulation or psychiatric illness. Self treatment by homemade instruments is a rarely seen scenario. A 62-year-old man presented to our department complaining of lower urinary tract symptoms. On examination, a foreign body was detected inside the urinary bladder. Urethral stricture was also detected for which the patient had been previously treated on several occasions. The patient stated that he had attempted self catheterization using a homemade catheter. He had succeeded in emptying his bladder; however, the catheter entered the bladder completely and was irretrievable to him. Sachse urethrotomy was performed following retrieval of the foreign body. No psychiatric illness was detected in our patient. The patient’s postoperative course was uneventful.Strana tijela unutar mokraćnog sustava su relativno rijetko stanje u našoj praksi. U većini objavljenih slučajeva razlog umetanja stranog tijela je autoerotska stimulacija ili psihijatrijska bolest. Umetanje stranog tijela kao povod za rješavanje mokraćne opstrukcije je rijedak događaj. Bolesnik u dobi od 62 godine javio se na našu kliniku zbog simptoma donjeg mokraćnog trakta. Tijekom pregleda otkriveno je strano tijelo unutar mokraćnog mjehura. Kod bolesnika je u više navrata rađena unutarnja uretrotomija, a jednom otvorena operacija uretre s terminoterminalnom anastomozom. Bolesnik je naveo da je pokušao samokateterizaciju s improviziranim kateterom. Uspio je riješiti mokraćnu opstrukciju, no dio stranog tijela je zaostao u mokraćnom mjehuru. Nakon dodatne obrade učinjena je unutarnja uretrotomija po Sachseu s ekstrakcijom stranog tijela iz mokraćnog mjehura. Psihijatrijskih bolesti se kod bolesnika ne nalazi

Nepovoljne kliničko-patološke značajke u bolesnika s izostavljenom limfadenektomijom tijekom radikalne prostatektomije

Pelvic lymph node dissection (PLND) during radical prostatectomy (RP) is the most accurate staging modality for lymph node assessment in patients with prostate cancer. It is recommended in all patients with intermediate or high-risk disease undergoing radical prostatectomy. The goal of our study was to assess unfavorable clinicopathological characteristics in patients with omitted lymphadenectomy (PLND) during radical prostatectomy based on the nomogram proposed by Briganti and colleagues. In 2011, 200 patients undertook radical prostatectomy in our institution. Among them 53 patients who fulfilled Briganti criteria and in whom we omitted lymphadenectomy based on current guidelines. Unfavorable clinicopathological features considered were: stage T3, positive surgical margins or biochemical relapse (BCR). We registered biopsy Gleason score 6 in 34 patients, and 19 patients had Gleason score 7. Stage pT2 was seen in 49 patients, and pT3 in 4. Gleason score after radical prostatectomy was upgraded from GS 6 to GS 7 in 20 patients (37%) and reduced in 1 patient (2%). After a median follow-up of 49 (44-56) months, there were 12 (22.6%) patients with BCR. Patients with biopsy Gleason score 6 (n=34) compared to biopsy Gleason 7 (n=19) patients showed no difference regarding positive margins (p=0.0738) and BCR (p=0,736) at 49 months follow-up. Thus, PLND according to current guidelines can be safely omitted in low-risk patients using Brigantinomogram.Zdjelična limfadenektomija u vrijeme radikalne prostatektomije (RP) trenutno je najpouzdaniji način otkrivanja metastaza u limfne čvorove u bolesnika s rakom prostate. Cilj našeg istraživanja bio je procijeniti nepovoljne kliničko-patološke značajke u bolesnika s izostavljenom limfadenektomijom tijekom radikalne prostatektomije temeljene na Briganteovom nomogramu. U 2011. godini, u našoj je ustanovi 200 bolesnika podvrgnuto radikalnoj prostatektomiji. Identificirali smo 53 bolesnika koji su ispunili Brigantijeve kriterije te su prema aktualnim smjernicama bili pošteđeni zdjelične limfadenektomije. Nepovoljnim kliničko-patološkim značajkama smatralo se bilježenje stadija T3 bolesti, pozitivni kirurški rubovi ili biokemijski relaps. Na patohistološkom (PH) nalazu biopsije Gleason zbroj 6 verificiran je u 34 pacijenta, a 19 je pacijenata imalo Gleason zbroj 7. Na konačnom PH nalazu nakon učinjene radikalne prostatektomije 49 bolesnika je imalo pT2 stadiji bolesti, a 4 su bolesnika imala pT3. Konačni Gleason zbroj nakon radikalne prostatektomije povećan je u 20 bolesnika na GS 7 (37%) i smanjen kod jednog bolesnika (2%). Nakon srednjeg praćenja od 49 (44-56) mjeseci, bilo je 12 (22,6%) bolesnika s biokemijskim relapsom (BR). Usporedba bolesnika s biopsijskim nalazom Gleason zbroja 6 (n = 34) i bolesnika s Gleason zbrojem7 (n = 19) nije pokazala značajnu razliku u odnosu na pozitivne kirurške rubove (p = 0,0738) i BR (p = 0,736) nakon 49 mjeseci praćenja. Stoga se zdjelična limfadenektomija prema aktualnim smjernicama može sigurno izostaviti u bolesnika s procijenjenim niskim rizikom koristeći Briganteov nomogram

Usporedba točnosti stupnjevanja diferencijacije raka prostate u uzorcima dobivenim ciljanom i sustavnom biopsijom prostate

All malignancies, including prostate cancer, require accurate diagnosing and staging before making a treatment decision. The introduction of targeted biopsies based on prostate MRI findings has raised prostate biopsy accuracy. Guided biopsies target the tumor itself during the biopsy instead of the most common tumor sites as is the case with a systemic biopsy. Some studies report that targeted biopsies should lower prostate cancer biopsy undergrading and overgrading. To determine the incidence of prostate cancer biopsy undergrading in patients who underwent a classic systemic biopsy compared to patients who underwent a mpMRI cognitive targeted biopsy. We identified the patients from our database who underwent a radical prostatectomy at our institution from January 1st, 2021, to June 30th, 2021.There were 112 patients identified. Patients were stratified into two groups based on the type of biopsy that confirmed prostate cancer. The mpMRI (N=50) group had a mpMRI cognitive guided transrectal ultrasound (TRUS) prostate biopsy performed, and the non-mpMRI group (N=62) received a classic, systemic TRUS biopsy. We compared the biopsy results with the final pathological results, and searched for undergrading or overgrading in the biopsies compared to the final histological reportThe undergrading was found in 17,7 % (N=11) cases in the non-mpMRI group and in 12,0 % (N=6) of cases in the mpMRI group (p=0,02, Mann-Whitney U test). No overgrading was found in our cohort. All cases of undergrading had Grade Group 1 in the biopsy report and Grade Group 2 in the final specimen report. The charasteristics of patients are listed in Table 1. In our cohort, the patients who underwent a mpMRI targeted biopsy had a lower undergrading incidence. During a systemic TRUS biopsy, the urologist targets the areas of the prostate where cancer is most commonly located, which is usually the peripheral zone of the prostate. Since different areas of the tumor have different areas of differentiation, only a low-grade part of the tumor is sometimes biopsied, which results in a sampling error. Once the prostate is removed, the whole tumor is analyzed, so the obtained pathological results related to the removed prostate are far more accurate than the analysis of prostate cores obtained by biopsy.Sve maligne bolesti, uključujući rak prostate, zahtijevaju preciznu dijagnostiku prije odluke o liječenju. Uvođenjem ciljanih biopsija na temelju nalaza MRI prostate povećana je točnost biopsije prostate. Vođene biopsije ciljaju na sam tumor u umjesto na najčešće lokacije tumora u prostati kao što je slučaj sa sistemskom biopsijom. Neke studije pokazuju da bi ciljane biopsije trebale smanjiti podcjenjivanje stupnja diferenciranosti raka prostate u uzorcima dobivenim biopsijom prostate. Odrediti incidenciju podcjenjivanje stupnja diferenciranosti raka prostate kod pacijenata koji su bili podvrgnuti klasičnoj sistemskoj biopsiji u usporedbi s pacijentima koji su bili podvrgnuti mpMRI kognitivnoj ciljanoj biopsiji. Identificirali smo pacijente iz naše baze podataka koji su podvrgnuti radikalnoj prostatektomiji u našoj ustanovi od 1. siječnja 2021. do 30. lipnja 2021. Identificirano je 112 pacijenata. Pacijenti su podijeljeni u dvije skupine na temelju vrste biopsije kojom je potvrđen rak prostate. Skupina mpMRI (N=50) primila je mpMRI kognitivno vođenu transrektalnu ultrazvučnu (TRUS) biopsiju prostate, a skupina non-mpMRI (N=62) primila je klasičnu, sistemsku TRUS biopsiju. Usporedili smo rezultate biopsije s konačnim patološkim nalazima i tražili smo podcjenjivanje stupnja diferenciranosti karcinoma prostate u biopsijama u usporedbi s konačnim histološkim nalazom. Podcjenjivanje stupnja diferenciranosti nađeno je u 17,7 % (N=11) u non-mpMRI skupini i u 12,0 % (N=6) slučajeva u mpMRI skupini (p=0,02, Mann-Whitney U test). U našoj kohorti nije pronađeno precjenjivanje stupnja diferenciranosti. Svi slučajevi podcjenjivanja imali su Gradus grupu 1 na nalazu biopsije prostate i Gradus grupu 2 u konačnom patohistološkom nalazu. U našoj kohorti, pacijenti koji su bili podvrgnuti ciljanoj biopsiji imali su nižu incidenciju podcjenjivanja stupnja diferenciranosti što je posljedica točnijeg uzorkovanja. Tijekom sistemske TRUS biopsije, urolog cilja na područja prostate gdje se rak najčešće nalazi, što je obično periferna zona prostate. Budući da različita područja tumora imaju različita područja diferencijacije, ponekad se bioptira samo dio tumora koji je bolje diferenciran, što rezultira pogreškom uzorkovanja. Nakon što je prostata uklonjena, analizira se cijeli tumor, tako da su rezultirajući patohistolološki rezultati uklonjene prostate daleko točniji od analize uzoraka prostate dobivenih biopsijom

Razvoj parcijalne nefrektomije zbog tumora bubrega – napuštamo li osnovna načela Robsonove radikalne nefrektomije?

Fifty years ago, Robson introduced radical nephrectomy (RN ) setting the gold standard for treating kidney tumors. Experience has shown that partial nephrectomy (PN) can be equally effective with the advantages of preserving kidney function and avoiding unnecessary nephrectomies for benign tumors. The purpose of this report is to demonstrate the evolution of clinical presentation and choice of treatment for patients with kidney tumors at our department, emphasizing changes in the PN utilization trends. Clinical data were abstracted for the years 2002, 2007 and 2012. We assessed annual trends for changes in the choice of operative treatment related to tumor size, pathologic stage and diagnosis. During the study, there was an increase in the share of T1 tumors, from 46.6% in 2002 to 69.8% in 2012. The rate of PN increased more than ten-fold, from 2.7% in 2002 to 31.7% in 2012. The annual rates of PN for T1 tumors increased even more, from 6.6% in 2002 to 46.7% in 2012. Opposite to RN group, there was an increase in the mean tumor size in PN group (from 1.8 cm in 2002 to 3.9 cm in 2012). The rate of RN for benign tumors was reduced impressively from 85.7% in 2002 to 23.1% in 2012. Our data argue strongly that PN should be expanded and not restricted. Robson’s principles have been partially deserted over the last decade; however, proving that PN is superior to RN still remains to be elucidated.Prije 50 godina Robson je izveo prvu radikalnu nefrektomiju (RN ) te time postavio zlatni standard za kirurško liječenje tumora bubrega. Iskustvo je pokazalo da je parcijalna nefrektomija (PN) jednako učinkovita s prednostima očuvanja bubrežne funkcije i izbjegavanjem nepotrebne nefrektomije zbog dobroćudnih tumora. U radu se prikazuju promjene kliničke slike i napredak u izboru operativnog liječenja tumora bubrega na našoj klinici, naglašavajući razvoj indikacija za primjenu PN. Studija je obuhvatila sve bolesnike koji su operativno liječeni zbog tumora bubrega na našoj klinici u 2002., 2007. i 2012. godini. Analizirali smo izbor operativne metode u danim razdobljima prema veličini tumora, stadiju bolesti i dijagnozi.U promatranom razdoblju porastao je udio tumora T1, s 46,6% u 2002. na 69,8% u 2012. godini. Od ukupnog broja operiranih bolesnika u 2002. godini 2,7% ih je operirano metodom PN, dok je u 2012. taj udio bio 32%, što predstavlja porast veći od 10 puta. Porast godišnjeg udjela PN za stadij bolesti T1 bio je još veći, sa 6,6% u 2002. na 46,7% u 2012. godini. Za razliku od skupine RN , u skupini PN zabilježen je porast prosječne veličine tumora s 1,8 cm u 2002. na 3,9 cm u 2012. godini. Impresivno je smanjenje RN kod bolesnika s dobroćudnom patologijom koja je u 2002. godini iznosila 85,7%, a u 2012. samo 23,1%. Rezultati našega istraživanja pokazuju da indikacije za PN treba proširivati, a ne ograničavati. U zadnjih 10 godina Robsonova načela su djelomice napuštena, ali superiornost PN nad RN tek treba dokazati

Povijest urologije u bolnici Sestara milosrdnica

The history of Croatian urology clearly shows its affiliation to the medical and civilizational circle of the Western world. The Department of Urology at the Sestre milosrdnice University Hospital Center is the oldest urology institution in the Republic of Croatia. The Department was established in 1894, when the new Sestre milosrdnice Hospital was open in Vinogradska cesta in Zagreb. It was then that doctor Dragutin Mašek founded the so-called III Department, which, in addition to treating urology patients, also treated patients with conditions of the ear, nose and throat, eye diseases and dermatologic conditions. Dragutin Mašek had already realized that medicine would soon be divided into fields and had assigned younger doctors joining the III Department to specific fields. As a result, urology was given to Aleksandar Blašković, who founded the first independent department of urology in Croatia in 1926. In 1927, he was appointed Professor of urology at the Zagreb School of Medicine, where he established the first department of urology and was giving lectures and practicals. Under his leadership, the Department of Urology was given the status of a Clinic, a teaching department, the first of its kind in Croatia. Owing to all his activities in the field of urology, the history remembers him as the “father of modern Croatian urology”. Over the course of the following years, department chairs had changed, but luckily for the patients, approach to work had not. Conscientiousness, trust, competence and charity. After all, charity is the idea that the hospital carries even in its name, after the Sisters of Charity who had founded it. In all the decades, the Department of Urology has been following global development paths, objectively legging behind top facilities in the world by only a few years. Overall professional and scientific urology activities culminated in 1998, when the Clinic became the Reference Center of the Ministry of Health of the Republic of Croatia for prostate cancer, and in 2011, when it became the European Board of Urology Certified Center. All that has been achieved could not have been done without wholehearted help and cooperation of the nurses, as well as every other department employee from the beginnings of urology until today. Despite its rich history, the Department does not rest on laurels. Today, it is a modern urology department together with its European role models.Prošlost hrvatske urologije jasno određuje njezinu pripadnost medicinskom i civilizacijskom krugu zapadnoga svijeta. Klinika za urologiju KBC “Sestre milosrdnice” najstarija je urološka ustanova u Republici Hrvatskoj. Osnovana je 1894. kad je otvorena nova Bolnica sestara milosrdnica u Zagrebu u Vinogradskoj ulici. Te je godine dr Dragutin Mašek osnovao tzv. III Odjel na kojem su se operativno zbrinjavali osim uroloških bolesnika, bolesnici sa bolestima uha, grla i nosa, sa očnim i dermatološkim bolestima. Dragutin Mašek već tada je vidio da će se medicina uskoro dijeliti na uža područja, pa je dolaskom mlađih liječnika na III. odjel njima prepuštao određena područja, tako da je urologiju preuzeo Aleksandar Blašković koji 1926. godine osniva prvi samostalni odjel za urologiju u Hrvatskoj. Imenovan je 1927. za profesora urologije na Medicinskom fakultetu u Zagrebu gdje osniva prvu katedru za urologiju i vodi predavanja i vježbe. Pod njegovim vodstvom Odjel za urologiju dobio 1943. godine status Klinike za urologiju, prve u Hrvatskoj. Temeljem svih tih aktivnosti na urološkom području povijest ga pamti kao „oca moderne hrvatske urologije“. U godinama koje slijede čelnici urologije su se mijenjali, a svjetonazor u radu na sreću bolesnika ne. Savjest, povjerenje, stručnost i milosrđe. Uostalom, to je znamen koji bolnica nosi u svom imenu. Svih tih desetljeća Klinika za urologiju je pratila suvremene svjetske pravce razvoja, objektivno kasneći tek nekoliko godina za vrhunskim ustanovama u svijetu. Cjelokupna stručna i znanstvena urološka djelatnost kulminira 1998. godine, kada Klinika postaje Referentni centar za tumore prostate Ministarstva zdravstva Republike Hrvatske i 2011. godine kada je postala Centar obuke Europskog odbora za urologiju (European Board of Urology). Sve postignuto ne bi se moglo ostvariti bez svesrdne pomoći i suradnje medicinskih sestara i drugih djelatnika klinike od prvih početaka urologije do današnjih dana. Unatoč bogatojj prošlosti, Klinika ne živi na uspjesima svojih prethodnika. Danas je ta urologija zajedno s njezinim uzorima europska moderna urologija

Transopturatorna AdVance® suspenzija u liječenju postoprostatektomijske stresne inkontinencije mokraće

Stress urinary incontinence (SUI) continues to present a major complication after radical prostatectomy. Suburethral slings represent one of the less invasive options for postprostatectomy SUI, and a more recent addition is a transobturator sling, the AdVance®. We report our results with the AdVance® sling for the management of postoperative SUI. The evaluation was conducted on 47 patients with AdVance® implant for SUI in our institution (November 2010 - June 2017). Measurements included age, etiology of SUI, duration of SUI, follow-up and pad use per day (PPD) pre- and postoperatively. Patients were classified as cured if they used no pads or 1 PPD for security reasons, or as improved if 1-2 PPDs were used and if there was a 50% reduction in pad use per day postoperatively. In our series we observed a reduction of mean PPD of 5.1 (2-8) to 1.7 (0-4) postoperatively. After follow-up and according to our criteria, the cure rate was 51.1% (24/47) and the improvement rate 27.5% (13/47). The overall success rate was 78.6% (37/47). No improvement was observed in 21.4% (10/47) of patients. Failure rates after sling placement for patients with additional treatments following prostatectomy were much higher (60% (3/10) for radiation therapy and 66.7% (4/10) for urethral stricture disease). Our results show favourable cure and improvement rates and are comparable to results from larger series. The most appropriate candidates for the AdVance® sling are patients with mild to moderate postprostatectomy SUI. The results may be even better in patients without additional treatment following prostatectomy, such as radiation therapy or surgery for stricture disease.Unatoč napretku u liječenju lokaliziranog raka prostate radikalnom prostatektomijom, i dalje je prisutan dio bolesnika kod kojih perzistira stresna urinarna inkontinencija (SUI). Suburetralni, a odnedavno i transopturatorni „slingovi“ zbog neinvazivnosti postaju metodom izbora u liječenju ovih bolesnika. U članku prikazujemo kiruršku tehniku i naše rezultate liječenja postoperativne SUI metodom AdVance®. Od studenog 2010. do lipnja 2017. metodom AdVance® na Klinici je operirano 47 bolesnika. Zabilježena je dob, etiologija i trajanje SUI te dnevni broj uložaka preoperativno i postoperativno. Izlječenje je definirano kao potpuna kontinencija ili korištenje jednog sigurnosnog uloška / dan. Poboljšanje je definirano kao korištenje 1-2 uloška / dan te smanjenje u dnevnom broju uložaka veće od 50%. U ispitivanom razdoblju kod operiranih bilježimo značajan pad prosječnog broja uložaka / dan s 5.1 (2-8) na postoperativno 1.7 (0-4). Prema našim kriterijima, postoperativno je kontinentno 51.1% (24/47), a poboljšanje kontinencije nalazimo kod 27.5% (13/47) operiranih. Kod 78.6% (37/47) operiranih broj dnevno korištenih uložaka smanjio se za više od 50% i/ili je kontinentno. Stope neuspjeha znatno su veće kod bolesnika koji su nakon prostatektomije tretirani radioterapijom (60% (3/10)) ili uretrotomijom (66.7% (4/10)). Rezultati liječenja postoperativne SUI suspenzijom AdVance® u našoj ustanovi usporedivi su s rezultatima do sada objavljenih studija. Suspenzija AdVance® indicirana je kod bolesnika s blagom do umjerenom postoperativnom SUI te očuvanom ostatnom funkcijom sfinktera potvrđenom uretrocistoskopijom. Očekivano, a zbog periuretralne fibroze, uspješnost metode upitna je kod bolesnika koji su nakon prostatektomije tretirani radioterapijom ili endourološkim zahvatima

20 godina Referentnog centra za tumore prostate Ministarstva zdravstva u Klinici za urologiju KBC Sestre milosrdnice

Department of Urology at the Sestre milosrdnice University Hospital Center is the oldest urological institution in the Republic of Croatia and this part of Europe. Today, the Department is a modern tertiary healthcare institution, where the most complex methods of urological practice are performed using modern medical devices and highly sophisticated technology. In 2011, our urology specialist education program was certified by the European Board of Urology (EBU) as the only one of its kind in Croatia. The program was recertified in 2017. The Department runs a program for the early detection of prostate cancer and performs more than 240 radical prostatectomies annually, which is the highest number of such interventions in Croatia. The aim of this study is to present the work and the activities of the Reference Center for Prostate Tumors of the Ministry of Health at the Department of Urology in Sestre milosrdnice University Hospital Center over the last 20 years. The database of the Reference Center for Prostate Tumors of the Ministry of Health at the Department of Urology in Sestre milosrdnice University Hospital Center was reviewed. During the twenty-year period, approx-imately 15,000 prostate interventions were performed due to benign and malignant diseases. Of this, 7,374 transrectal ultrasound guided prostate biopsies, 2,632 radical prostatectomies with open retropubic access, 3,988 transurethral prostate resections and 1,097 open suprapubic adenomectomies were performed. With the achieved scientific and professional results in monitoring, studying and improving the prevention, diagnosis and therapy of prostate tumors, as well as with the professional conditions and personnel, the Department of Urology in Sestre milosrdnice University Hospital Center truly justifies the title of the Reference Center for Prostate Tumors of the Ministry of Health of the Republic of Croatia awarded to it in 1998Klinika za urologiju Kliničkog bolničkog centra Sestre milosrdnice najstarija je urološka ustanova u Republici Hrvatskoj, a i u ovom dijelu Europe. Danas je Klinika za urologiju moderna medicinska ustanova tercijarne zdravstvene zaštite gdje se najsloženije metode urološke prakse izvode pomoću suvremenih medicinskih uređaja i visoko sofisticirane tehnologije. Program edukacije specijalizanata je 2011. godine certificiran od strane European Board of Urology (EBU) kao jedini takav u Hrvatskoj, a recertificiran je 2017. godine. U našoj se Klinici provodi program ranog otkrivanja raka prostate, a godišnje se obavlja preko 240 radikalnih prostatektomija što je ujedno i najveći broj takvih zahvata u Hrvatskoj. Cilj rada je prikazati rad i aktivnost Referentnog centra Ministarstva zdravstva za tumore prostate u Klinici za urologiju KBC „Sestre milosrdnice“ u posljednjih 20 godina. Učinjen je pregled baze podataka Referentnog centra za tumore prostate Ministarstva zdravstva u Klinici za urologiju KBC „Sestre milosrdnice“. Tijekom dvadesetogodišnjeg razdoblja učinjeno je oko 15 000 zahvata na prostati zbog benignih i malignih bolesti. Od toga je učinjena 7 374 biopsija prostate vođene transrektalnim ultrazvukom, 2 632 radikalnih prostatekomija otvorenim retropubičnim pristupom, 3 988 transuretralnih resekcija prostate i 1 097 otvorenih suprapubičnih adenomektomija. Postignutim znanstvenim i stručnim rezultatima u praćenju, proučavanju i unaprjeđenju prevencije, dijagnostike i terapije tumora prostate kao i stručno-kadrovskim uvjetima, Klinika za urologiju KBC Sestre milosrdnice opravdava naslov Referentnog centra za tumore prostate Ministarstva zdravstva Republike Hrvatske koji nosi od 1998. godine

Unfavorable Clinicopathological Features in Radical Prostatectomy Patients Who Were Spared Pelvic Lymphadenectomy

Pelvic lymph node dissection (PLND) during radical prostatectomy (RP) is the most accurate staging modality for lymph node assessment in patients with prostate cancer. It is recommended in all patients with intermediate or high-risk disease undergoing radical prostatectomy. The goal of our study was to assess unfavorable clinicopathological characteristics in patients with omitted lymphadenectomy (PLND) during radical prostatectomy based on the nomogram proposed by Briganti and colleagues. In 2011, 200 patients undertook radical prostatectomy in our institution. Among them 53 patients who fulfilled Briganti criteria and in whom we omitted lymphadenectomy based on current guidelines. Unfavorable clinicopathological features considered were: stage T3, positive surgical margins or biochemical relapse (BCR). We registered biopsy Gleason score 6 in 34 patients, and 19 patients had Gleason score 7. Stage pT2 was seen in 49 patients, and pT3 in 4. Gleason score after radical prostatectomy was upgraded from GS 6 to GS 7 in 20 patients (37%) and reduced in 1 patient (2%). After a median follow-up of 49 (44-56) months, there were 12 (22.6%) patients with BCR. Patients with biopsy Gleason score 6 (n=34) compared to biopsy Gleason 7 (n=19) patients showed no difference regarding positive margins (p=0.0738) and BCR (p=0,736) at 49 months follow-up. Thus, PLND according to current guidelines can be safely omitted in low-risk patients using Brigantinomogram

Transobturator Advance® Sling Suspension for the Treatment of Postprostatectomy Stress Urinary Incontinence

Stress urinary incontinence (SUI) continues to present a major complication after radical prostatectomy. Suburethral slings represent one of the less invasive options for postprostatectomy SUI, and a more recent addition is a transobturator sling, the AdVance®. We report our results with the AdVance® sling for the management of postoperative SUI. The evaluation was conducted on 47 patients with AdVance® implant for SUI in our institution (November 2010 - June 2017). Measurements included age, etiology of SUI, duration of SUI, follow-up and pad use per day (PPD) pre- and postoperatively. Patients were classified as cured if they used no pads or 1 PPD for security reasons, or as improved if 1-2 PPDs were used and if there was a 50% reduction in pad use per day postoperatively. In our series we observed a reduction of mean PPD of 5.1 (2-8) to 1.7 (0-4) postoperatively. After follow-up and according to our criteria, the cure rate was 51.1% (24/47) and the improvement rate 27.5% (13/47). The overall success rate was 78.6% (37/47). No improvement was observed in 21.4% (10/47) of patients. Failure rates after sling placement for patients with additional treatments following prostatectomy were much higher (60% (3/10) for radiation therapy and 66.7% (4/10) for urethral stricture disease). Our results show favourable cure and improvement rates and are comparable to results from larger series. The most appropriate candidates for the AdVance® sling are patients with mild to moderate postprostatectomy SUI. The results may be even better in patients without additional treatment following prostatectomy, such as radiation therapy or surgery for stricture disease